Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 5, 2017, Pages

  D'Angelo, Arianna ^a   Amso, Nazar N ^a   Hassan, Rudaina ^b  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; CHORIONIC GONADOTROPIN; FOLLITROPIN; GONADORELIN ANTAGONIST; ERGOLINE DERIVATIVE; GONADORELIN;

ADULT; COASTING; COMPARATIVE EFFECTIVENESS; EARLY UNILATERAL FOLLICULAR ASPIRATION; FEMALE; FOLLICULAR ASPIRATION; HORMONAL THERAPY; HUMAN; LIVE BIRTH; MAJOR CLINICAL STUDY; MULTIPLE PREGNANCY; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; PREGNANCY RATE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; IN VITRO FERTILIZATION; META ANALYSIS; PREGNANCY; STATISTICS AND NUMERICAL DATA; TREATMENT WITHDRAWAL;

ABORTION, SPONTANEOUS; CHORIONIC GONADOTROPIN; ERGOLINES; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LIVE BIRTH; OVARIAN HYPERSTIMULATION SYNDROME; PREGNANCY; PREGNANCY RATE; PREGNANCY, MULTIPLE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WITHHOLDING TREATMENT;

EID: 85019896316     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD002811.pub4     Document Type: Review

References (40)

1. Aboulghar M, Mansour R, Amin Y, Al-Inany H, Aboulghar M, Serour G. A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS. Reproductive Biomedicine Online 2007;15(3):271-9. 2976815
2. Aflatoonian A, Mahani I, Tabibnejad N, Aflatoonian B, Aflatoonian R. Comparison of coasting with aspiration half of follicles before hCG injection for prevention of OHSS in ART cycles. Human Reproduction 2006;21(Suppl 1):i37. 2976817
3. Dalal R, Mishra A. Comparison of coasting with cabergoline administration for prevention of early severe OHSS in ART cycles. BJOG Eposter 2014:78. 5659020
4. Egbase PE, Al Sharhan M, Grudzinskas JG. Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. Human Reproduction 1999;14(6):1421-5. 2976819
5. Egbase P, Al Sharhan M, Masangcay M, Egbase E. Follicle stimulating hormone (FSH) administer with trigger dose human chorionic gonadotropin (hCG) completely prevents ovarian hyperstimulation syndrome (OHSS). Randomised controlled trial. Fertility and Sterility 2011;96(3):S20. 2976821
6. Kamthane V, Goswami S, Ghosh S, Chattopadhay R, Chakravarty B. Does coasting prevent OHSS without compromising pregnancy outcome?. Human Reproduction 2004;19 Suppl(6):i121. 2976823
7. Lukaszuk K, Liss J, Jakiel G. 'Internal Coasting' for prevention of ovarian hyperstimulation syndrome (OHSS) in IVF/ICSI. Ginekol Pol 2011;82:812-6. 2976825
8. Sohrabvand F, Ansaripour MD, Bagheri M, Shariat M, Jafarabadi M. Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive outcome in high risk patients. International Journal of Fertility and Sterility 2009;3(1):35-40. 5659022
9. Aboulghar MA, Mansour RT, Serour GI, Sattar M, Ranzy AM, Amin Y. Successful prevention of ovarian hyperstimulation syndrome by reduction of human menopausal gonadotrophin dose following by delayed HCG injection. Human Reproduction 1998;13:243-4. 2976827
10. Al-Shawaf T, Zosmer A, Hussain S, Tozer A, Panay N, Wilson C, et al. Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer: a modified 'coasting' strategy based on ultrasound identification of high-risk patients. Human Reproduction 2001;1(16):24-30. 2976829
11. Benadiva CA, Davis O, Kligman I, Moomjy M, Hung-Ching L, Rosenwaks Z. Withholding gonadotropin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome. Fertility and Sterility 1997;67(4):724-7. 2976831
12. Dhont M, Van der Straeten F, De Sutter P. Prevention of severe ovarian hyperstimulation by coasting. Fertility and Sterility 1998;70(9):847-50. 2976833
13. Esinler I, Bozdag G. Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting. Archives of Gynecology and Obstetrics 2013;288:1159-63. 5659024
14. Fluker MR, Hooper WM, Yuzpe A. Withholding gonadotropins ('coasting') to minimize the risk of ovarian hyperstimulation during superovulation and in vitro fertilization-embryo transfer cycles. Fertility and Sterility 1999;71(2):294-301. 2976835
15. Herrero L, Pareja S, Losada C, Cobo AC, Pellicer A, Garcia-Velasco . Avoiding the use of human chorionic gonadotrophin combined with oocyte vitrification and GnRH agonist versus coasting: a new strategy to avoid ovarian hyperstimulation syndrome.. Fertility and Sterility 2011;95(3):1137-40. 5659026
16. Lee C, Tummon I, Martin J, Nisker J, Power S, Tekpetey F. Does withholding gonadotropin administration prevent severe ovarian hyperstimulation syndrome?. Human Reproduction 1998;13(5):1157-8. 2976837
17. Sher G, Zouves C, Feinman M, Maassarani G. 'Prolonged coasting': an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization. Human Reproduction 1995;10(12):3107-9. 2976839
18. Tortoriello DV, McGovern P, Colon JM, Skurnick JH, Lipetz K, Santoro N. 'Coasting' does not adversely affect cycle outcome in a subset of highly responsive in vitro fertilization patients. Fertility and Sterility 1998;69(3):454-60. 2976841
19. Tortoriello DV. Exogenous gonadotropin withdrawal for the prevention of severe ovarian hyperstimulation syndrome: a critical review. Assisted Reproduction 1999;9(1):17-22. 2976843
20. Ulug U, Bahceci M, Erden HF, Shalev E, Ben-Shlomo I. The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Human Reproduction 2002;17(2):310-3. 2976845
21. Van der Straeten F, De Sutter P, Dhont M. Prevention of threatening ovarian hyperstimulation by coasting. Assisted Reproduction 1998;21(4):200-4. 2976847
22. Waldenstrom U, Kahn J, Marsk L, Nilsson S. High pregnancy rates and successful prevention of severe ovarian hyperstimulation syndrome by 'prolonged coasting' of very hyperstimulated patients: a multicentre study. Human Reproduction 1999;14(2):294-7. 2976849
23. Agrawal R, Tan SL, Wild S, Sladkevicius P, Engnrann L, Payne N, et al. Serum vascular endothelium growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertility and Sterility 1999;71:287-93.
24. Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertility and Sterility 2016;106:1634-47.
25. Calhaz-Jorge C, De Geyter C, Kupka MS, de Mouzon, Erb K, Mocanu E, et al. Assisted reproductive technology in Europe, 2012: results generated from European registers by ESHRE. Human Reproduction 2016;31(8):1638-52.
26. Golan A, Ron-El R, Herman A, Soffer Y, Wainraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstetrical and Gynaecological Survey 1989;44:430-40.
27. Goldsman MP, Pedram A, Dominiguez CE, Ciuffardi I, Levin E, Asch RH. Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertility and Sterility 1995;63:268-72.
28. GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed prior to November 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
29. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
30. Kawwass JF, Kissin DM, Kulkarni AD, Creanga AA, Session DR, Callaghan WM, et al. Safety of assisted reproductive technology in the United States, 2000-2011. JAMA 2015;313(1):88.
31. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertility and Sterility 1992;58:249-61.
32. Rabau E, Serr DM, David A, Mashiach S, Lunenfield B. Human menopausal gonadotrophins for anovulation and sterility. American Journal of Obstetrics and Gynaecology 1967;98:92-8.
33. Rizk B, Aboulghar MA. Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In: Brinsden P editor(s). A Textbook of In Vitro Fertilization and Assisted Reproduction. 2nd Edition. London: Parthenon Publishing, 1999:131-55.
34. Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: a current survey. Fertility and Sterility 1978;30:255-68.
35. Sher G, Salem R, Feinman M, Dodge S, Zouves C, Knutzen V. Eliminating the risk of life-endangering complications following overstimulation with menotropin fertility agents: a report on women undergoing in vitro fertilization and embryo transfer. Obstetrics and Gynaecology 1993;81(6):1009-11.
36. Tsirigotis M, Craft I. Ovarian hyperstimulation syndrome (OHSS): how much do we really know about it?. European Journal of Obstetrics and Gynecology 1994;55(3):151-5.
37. D'Angelo A, Amso N. "Coasting" (withholding gonadotropins) for the treatment of Ovarian Hyperstimulation Syndrome. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD002811]
38. D'Angelo A, Amso N. "Coasting" (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD002811]
39. D'Angelo A, Brown J, Amso NN. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD002811]
40. D'Angelo A, Brown J, Amso NN. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews 2011, Issue 6. [DOI: 10.1002/14651858.CD002811]